drugset / Trial / NCT02779114

RETRO (REduction of Therapy in RA Patients in Ongoing Remission)

NCT02779114 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 3, multicenter, randomized, open, prospective, controlled, parallel-group intervention study in 318 patients with Rheumatoid Arthritis. The study is composed of 3 phases: a pre-randomization phase for up to 10 days followed by a 1-year randomized, open three arm treatment phase for each patient, followed by a 5-year observational phase for all patients still in remission.

Timeline

Start
2009-01
Primary completion
2017-12
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified — —
Subject Adalimumab Monoclonal antibody — —
Subject Azathioprine Small molecule — —
Subject Certolizumab Protein / enzyme biologic — —
Subject Cyclosporine Peptide — —
Subject Decortin H Unknown — —
Subject Etanercept Protein / enzyme biologic — —
Subject Golimumab Monoclonal antibody — —
Subject Hydroxychloroquine Small molecule — —
Subject Infliximab Monoclonal antibody — —
Subject Leflunomide Small molecule — —
Subject Methotrexate Small molecule — —
Subject Sulfasalazine Small molecule — —
Subject Tocilizumab Monoclonal antibody — —

Indications